European Pharmaceutical Students' Association

SpyBiotech Appoints Industry Veteran Eddie Gray as Chair of its Board of Directors

Retrieved on: 
Monday, February 13, 2023
Oncology, Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, MBA, Independent, Infection, Corporation, European Pharmaceutical Students' Association, Patient, VLP, Government of the United Kingdom, GSK plc, Lonrho, Eddie, Grey, Hepatitis B, Knowledge, IPSO, Independent Press Standards Organisation, FDA, HPV Prevention and Control Board, Conditional sentence, Cancer, Vaccine, Pharmaceutical industry

SpyBiotech , a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Eddie Gray, MBA, as Chairman of its Board of Directors.

Key Points: 
  • SpyBiotech , a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Eddie Gray, MBA, as Chairman of its Board of Directors.
  • Gray joins the Board as an independent director.
  • He is a Board member of The Independent Press Standards Organisation (IPSO), the UK press regulatory body.
  • “I am excited to join SpyBio’s Board of Directors as Chair as the company progresses its first vaccine candidate into the clinic,” said Eddie Gray.

European Pharmaceutical & Biotechnology Company Directory 2023: Contact Information for 5000+ Companies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 25, 2023
Biotechnology, Pharmaceutical, Health, European Pharmaceutical Students' Association, Internet, Publishing

Access a wealth of quality information on healthcare companies.

Key Points: 
  • Access a wealth of quality information on healthcare companies.
  • Look at the depth of information you'll get in the European Pharmaceutical Directory:
    Names of key management and trading personnel.
  • Locations of offices, sales offices and overseas sales agencies.
  • 6 Great Reasons to order your copy of The European Pharmaceutical Directory:
    Save time: no need to search the internet, all the information you need is in one handy guide;
    Save money: by using a resourceful book that details all your business contacts activities;
    Gain an understanding of the key players in this increasingly dominant market: quickly and easily
    Update your contact list: from the most reliable source in the industry.

Bell Let's Talk announces $1M in funding for post-secondary student mental health programs

Retrieved on: 
Wednesday, January 12, 2022
Well, United States Public Health Service, Research, Mental health, LinkedIn, Hope, European Pharmaceutical Students' Association, COVID-19, Achievement Medal, Organization, Access, Bell Let's Talk, Talk, Learning, Wellness, McMaster, Internet Standard, Specialised Technical Committees of the African Union, Instagram, School, Canadian Alliance of Student Associations, Bell, Facebook, Health, Program, Faculty, Association, Standard, University of Toronto School of Public Policy and Governance, Associate, YouTube, University of Toronto, TikTok, Dean, McMaster University, Twitter, Hospital, Pinterest, Partnership, University, Ministry of Health & Wellness, MONTRAL, Medicine, Television, Management, Mobile phone, Student

We are proud to continue our support of post-secondary institutions' efforts to expand, enhance or establish programs that support student mental health and well-being, and ultimately student success."

Key Points: 
  • We are proud to continue our support of post-secondary institutions' efforts to expand, enhance or establish programs that support student mental health and well-being, and ultimately student success."
  • - Janine Robb, Executive Director of Health & Wellness, University of Toronto
    Schools like Cgep de Sherbrooke are using Bell Let's Talk funds to implement campus programs to support the current mental health needs of their students.
  • "We are thrilled to receive a Bell Let's Talk Implementation Grant to help establish McMaster's Student Urgent Response Team (SURT), a mental health outreach and support service to assist our students facing a mental health crises.
  • Strengthening programs and services in support of student mental health is a collective effort, and we're very grateful for our partnership with Bell Let's Talk."

A healthcare market research reports platform that offers built in primary research, complimentary expert connects and much more

Retrieved on: 
Friday, October 15, 2021
Forecasting, Interview, Industry, Growth, European Pharmaceutical Students' Association, Health, Lists of people executed in the United States, Benchmarking, Health care, Grade (consulting), GRG, COVID, Biotechnology, Research, Pharmaceutical industry, Public relations, Marketing

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- GRG Health, a global leader in healthcare insights launches healthcare market insight reports platform Growth+ Market Reports powered with expert interviews and complimentary analysts' hours with each report.

Key Points: 
  • NEW YORK, Oct. 15, 2021 /PRNewswire/ -- GRG Health, a global leader in healthcare insights launches healthcare market insight reports platform Growth+ Market Reports powered with expert interviews and complimentary analysts' hours with each report.
  • GRG Health a global market leader in healthcare expert interviews with access to healthcare professionals across 50+ countries are addressing the unmet need of high quality primary research powered reports with Growth Plus Market Reports.
  • Growth + Market Reports, is a global life sciences market research reports platform that offers high quality market insights reports with a unique GrowthMIX approach.
  • All Growth+ reports come loaded with primary research, however the most differentiating factor remains complimentary access to Expert Connects Globally and Analyst Hours to build customizations complimentary with each report.

A healthcare market research reports platform that offers built in primary research, complimentary expert connects and much more

Retrieved on: 
Friday, October 15, 2021
Forecasting, Interview, Industry, Growth, European Pharmaceutical Students' Association, Health, Lists of people executed in the United States, Benchmarking, Health care, Grade (consulting), GRG, COVID, Biotechnology, Research, Pharmaceutical industry, Public relations, Marketing

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- GRG Health, a global leader in healthcare insights launches healthcare market insight reports platform Growth+ Market Reports powered with expert interviews and complimentary analysts' hours with each report.

Key Points: 
  • NEW YORK, Oct. 15, 2021 /PRNewswire/ -- GRG Health, a global leader in healthcare insights launches healthcare market insight reports platform Growth+ Market Reports powered with expert interviews and complimentary analysts' hours with each report.
  • GRG Health a global market leader in healthcare expert interviews with access to healthcare professionals across 50+ countries are addressing the unmet need of high quality primary research powered reports with Growth Plus Market Reports.
  • Growth + Market Reports, is a global life sciences market research reports platform that offers high quality market insights reports with a unique GrowthMIX approach.
  • All Growth+ reports come loaded with primary research, however the most differentiating factor remains complimentary access to Expert Connects Globally and Analyst Hours to build customizations complimentary with each report.

Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

Retrieved on: 
Thursday, September 16, 2021
Central nervous system, Therapy, CEO, Retinitis pigmentosa, Retina, RP, Patient, Company, Pharma, Neurological disorder, PDE6B, European Pharmaceutical Students' Association, Safety, IRD, Degenerative disease, Severe cognitive impairment, CNS, EU27, University, TOI, Partnership, AAV, Research, Pharmaceutical industry, Fine chemical, Vaccine

The agreement covers Coave's lead investigational gene therapy candidate CTx-PDE6b (formerly HORA-PDE6b) for patients with PDE6b-associated Retinitis Pigmentosa (RP), an inherited retinal disease (IRD).

Key Points: 
  • The agreement covers Coave's lead investigational gene therapy candidate CTx-PDE6b (formerly HORA-PDE6b) for patients with PDE6b-associated Retinitis Pigmentosa (RP), an inherited retinal disease (IRD).
  • "We are delighted to sign this agreement with Tha for CTx-PDE6b, our most advanced candidate, which represents an innovative new gene therapy for people with Retinitis Pigmentosa," said Rodolphe Clerval, CEO of Coave.
  • Under the terms of the agreement, Coave will receive an upfront payment and equity investment of 10 million from Tha.
  • Coave is also eligible to receive up to 65 million for achieving specified clinical development, regulatory and commercial milestones with CTx-PDE6b.

Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

Retrieved on: 
Thursday, September 16, 2021
European Union, Central nervous system, Therapy, CEO, Retinitis pigmentosa, Retina, RP, Patient, Union, Company, Pharma, Neurological disorder, PDE6B, European Pharmaceutical Students' Association, Safety, IRD, Degenerative disease, Severe cognitive impairment, CNS, EU27, University, TOI, Partnership, AAV, Research, Security (finance), Pharmaceutical industry, Fine chemical, Vaccine

PARIS, Sept. 16, 2021 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases, has entered into an exclusive licensing, co-development and commercialization agreement with Théa, a leading European speciality Pharma focused on ophthalmology. The agreement covers Coave's lead investigational gene therapy candidate CTx-PDE6b (formerly HORA-PDE6b) for patients with PDE6b-associated Retinitis Pigmentosa (RP), an inherited retinal disease (IRD).

Key Points: 
  • The agreement covers Coave's lead investigational gene therapy candidate CTx-PDE6b (formerly HORA-PDE6b) for patients with PDE6b-associated Retinitis Pigmentosa (RP), an inherited retinal disease (IRD).
  • "We are delighted to sign this agreement with Tha for CTx-PDE6b, our most advanced candidate, which represents an innovative new gene therapy for people with Retinitis Pigmentosa," said Rodolphe Clerval, CEO of Coave.
  • Under the terms of the agreement, Coave will receive an upfront payment and equity investment of 10 million from Tha.
  • Coave is also eligible to receive up to 65 million for achieving specified clinical development, regulatory and commercial milestones with CTx-PDE6b.

Abingworth strengthens investment team with new appointments in the US and UK

Retrieved on: 
Wednesday, September 15, 2021
Neurology, Investment, Peking University, University, CA, Partner, Private equity, Bachelor of Science, ZS Associates, McKinsey & Company, Doctor of Philosophy, Neuroscience, Bachelor of Medicine, Bachelor of Surgery, ZS, Medicine, European Pharmaceutical Students' Association, Principal, List of life sciences, National Hospital for Neurology and Neurosurgery, Consultant, Clinical Neuropharmacology, Imperial College London, Campbell Alliance, UCLH, MBA, L.E.K. Consulting, Thakeham, University College London, Chicago (franchise), Management, Pharmaceutical industry

LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.

Key Points: 
  • LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.
  • Jay will be based at the firm's Menlo Park, CA office and Lucille and Diya will be based in London, UK.
  • ABV 8 Abingworth Bioventures 8; ACCD2 Abingworth Clinical Co-Development Fund 2
    Abingworth is a leading transatlantic life sciences investment firm.
  • Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston

Abingworth strengthens investment team with new appointments in the US and UK

Retrieved on: 
Wednesday, September 15, 2021
Neurology, Investment, Peking University, University, CA, Partner, Private equity, Bachelor of Science, ZS Associates, McKinsey & Company, Doctor of Philosophy, Neuroscience, Bachelor of Medicine, Bachelor of Surgery, ZS, Medicine, European Pharmaceutical Students' Association, Principal, List of life sciences, National Hospital for Neurology and Neurosurgery, Consultant, Clinical Neuropharmacology, Imperial College London, Campbell Alliance, UCLH, MBA, L.E.K. Consulting, Thakeham, University College London, Chicago (franchise), Management, Pharmaceutical industry

LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.

Key Points: 
  • LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.
  • Jay will be based at the firm's Menlo Park, CA office and Lucille and Diya will be based in London, UK.
  • ABV 8 Abingworth Bioventures 8; ACCD2 Abingworth Clinical Co-Development Fund 2
    Abingworth is a leading transatlantic life sciences investment firm.
  • Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston